

10/538758  
JC06 Rec'd PCT/PTO 10 JUN 2005

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q88484

Hiromu HABASHITA, et al.

Appln. No.: National Stage Entry of PCT/JP03/15718

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: June 10, 2005

Examiner: Unknown

For: NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE  
THEREOF

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith on CD-ROM, along with a copy of the corresponding Communication from a Foreign Patent Office, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

10/538758  
JC06 Rec'd PCT/PTO 10 JUN 2005

INFORMATION DISCLOSURE STATEMENT  
U.S. Appln. No.: National Stage Entry of PCT/JP03/15718  
Attorney Docket No.: Q88484


The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of an English Language International Search Report from the International Searching Authority in the International Application, including at least that portion of the International Search Report indicating the degree of relevance found by the International Searching Authority.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,



Mark Boland  
Registration No. 32,197

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE  
23373  
CUSTOMER NUMBER

Date: June 10, 2005

Substitute for Form 1449 A & B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet <b>1</b> of <b>1</b>				Application Number Confirmation Number Filing Date First Named Inventor Art Unit Examiner Name Attorney Docket Number	National Stage Entry of PCT/JP03/15718 Unknown June 10, 2005 Hiromu HABASHITA Unknown Unknown Q88484

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)	
		US		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>	
		Country Code <sup>3</sup>	Number 1968 <sup>4</sup>			Kind Code <sup>5</sup> (if known)
		WO	00/56729	A1	09-28-2000	Anormed Inc.
		WO	02/22599	A2	03-21-2002	Anormed Inc.
		WO	01/040227	A1	06-07-201	Ono Pharmaceutical Co., Ltd.
		JP	2002-348288	A	12-04-2002	Ono Pharmaceutical Co., Ltd.
		WO	2002/45652	A2	06-13-2002	Merck & Co.
		GB	1113918	A	05-15-1968	Farbenfabriken Bayer AG.
		WO	2003/062236	A1	07-31-2003	Warner-Lambert Co.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.			Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number 1968 <sup>4</sup>	Kind Code <sup>5</sup> (if known)	
		GUPTA, C.M. et al, "Drugs acting on the central nervous system. Synthesis of substituted quinazolinones and quinazolines and triazepino- and triazocinoquinazolinones", Journal of Medical Chemistry, vol. 11, no. 2, (1968), pages 392-395			
		International Search Report dated February 17, 2004			

Examiner Signature	Date Considered	
--------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.